Previous PostJune 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
Next PostMay 15, 2025: MaaT Pharma : Présentation investisseurs, Stratégie et Perspectives 2025 - La Bourse et La Vie (French Only)
